Avelumab shows effectiveness against Merkel cell carcinoma (MCC) in a real-world population, extending evidence for the anti-PD-L1 antibody beyond the controlled trial setting, Medscape reports.

The finding matters because MCC is a rare and aggressive skin cancer, and outcomes observed in clinical trials do not always hold up once a therapy reaches routine practice. Real-world cohorts typically include older patients, patients with comorbidities, and patients whose disease characteristics would have excluded them from registration studies.

What does the real-world evidence show?

According to the report, avelumab performed effectively against MCC outside the trial environment. The coverage signals that responses observed among treated patients align with what clinicians would expect based on the drug's established profile in this indication.

The source article does not detail the specific cohort size, median follow-up, or response rates, so clinicians should consult the full Medscape report and the underlying study publication for the precise effect sizes and durability data.

Why this matters for dermatology practice

MCC is among the skin cancers dermatologists detect and co-manage, alongside melanoma and advanced squamous cell carcinoma. Immune checkpoint inhibitors have reshaped the treatment of advanced MCC, and avelumab is a key option in that armamentarium.

Real-world effectiveness data serve a distinct function from pivotal trial results. They tell practicing clinicians — including the dermatologists who make the initial diagnosis and coordinate referrals — whether the benefits seen in selected trial populations translate to the heterogeneous patients who present in community settings.

For referring dermatologists, the signal supports continued confidence in early referral of advanced or metastatic MCC patients to medical oncology for immunotherapy evaluation.

What remains to be seen

Longer-term follow-up from real-world registries will help define durability of response, tolerability in frailer patients, and outcomes in subgroups underrepresented in trials. The reported real-world effectiveness of avelumab in MCC adds a practical layer of evidence that clinicians can weigh as they counsel patients with this aggressive skin cancer.